FDA Advisory Committee Unanimously Recommends Moderna's mRNA Flu Vaccine for Adults 50 and Older

An FDA advisory panel has unanimously voted 9-0 to recommend approval of Moderna's mRNA-based influenza vaccine, mRNA-1010, for adults aged 50 and older. This recommendation, which exceeded expectations given prior FDA skepticism, validates robust Phase 3 clinical trial data published in the New England Journal of Medicine. The vaccine demonstrated a relative efficacy of 26.6% against RT-PCR-confirmed influenza-like illness and 47.9% against higher-level healthcare outcomes. The mRNA platform is noted for its potential to offer faster strain reformulation and a longer-lasting, broader immune response. The final FDA approval decision is anticipated by August 5, 2026.

Context

Moderna's mRNA-1010 vaccine is based on the same technology that underpinned its COVID-19 vaccine, which was widely adopted and shown to be effective. The Phase 3 clinical trial data published in the New England Journal of Medicine indicates that this flu vaccine could provide meaningful protection against influenza. The FDA's initial skepticism highlights the challenges faced by new vaccine technologies in gaining regulatory approval.

Why it matters

The unanimous recommendation by the FDA advisory panel is significant as it suggests a potential new tool in combating influenza for older adults, a group at higher risk for severe illness. The mRNA technology used in the vaccine has shown promise in previous applications, particularly during the COVID-19 pandemic. Approval could lead to improved public health outcomes and reduced healthcare costs associated with flu-related complications.

Implications

If approved, the vaccine could significantly impact vaccination rates among older adults, potentially leading to fewer hospitalizations and deaths from influenza. The success of this mRNA vaccine could pave the way for similar approaches to other vaccines, influencing future vaccine development strategies. Public health agencies may need to adjust their flu vaccination campaigns to incorporate this new option.

What to watch

The final decision from the FDA is expected by August 5, 2026, which will determine the vaccine's availability. Stakeholders will be monitoring public health responses and potential recommendations from the CDC regarding the vaccine's use in the target population. Additionally, the response from healthcare providers and patients will be crucial in shaping the vaccine's rollout.